Idexx Laboratories Inc. (NASDAQ:IDXX)’s share price hit a new 52-week high on Tuesday . The company traded as high as $95.50 and last traded at $94.51, with a volume of 149,621 shares traded. The stock had previously closed at $94.60.

Several equities research analysts have recently commented on the stock. Stifel Nicolaus upped their price target on shares of Idexx Laboratories from $80.00 to $85.00 and gave the company a “buy” rating in a research report on Monday, March 21st. Canaccord Genuity reaffirmed a “buy” rating and set a $85.00 price target (up previously from $80.00) on shares of Idexx Laboratories in a research report on Tuesday, April 19th. CL King assumed coverage on shares of Idexx Laboratories in a research report on Friday, April 1st. They set a “neutral” rating for the company. Zacks Investment Research raised shares of Idexx Laboratories from a “hold” rating to a “buy” rating and set a $88.00 price target for the company in a research report on Wednesday, March 30th. Finally, Credit Suisse Group AG upped their price target on shares of Idexx Laboratories from $80.00 to $85.00 and gave the company an “outperform” rating in a research report on Wednesday, April 13th. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Idexx Laboratories has an average rating of “Buy” and an average target price of $81.25.

The stock has a market capitalization of $8.44 billion and a P/E ratio of 45.54. The stock has a 50 day moving average of $90.02 and a 200-day moving average of $79.61.

Idexx Laboratories (NASDAQ:IDXX) last posted its earnings results on Friday, April 29th. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.04. The company earned $417.55 million during the quarter, compared to analysts’ expectations of $403.48 million. During the same quarter last year, the firm earned $0.49 EPS. Idexx Laboratories’s revenue for the quarter was up 9.3% on a year-over-year basis. On average, equities research analysts predict that Idexx Laboratories Inc. will post $2.21 earnings per share for the current fiscal year.

In other Idexx Laboratories news, Director William T. End sold 4,924 shares of the firm’s stock in a transaction dated Thursday, May 5th. The stock was sold at an average price of $85.87, for a total value of $422,823.88. Following the completion of the sale, the director now owns 63,578 shares of the company’s stock, valued at $5,459,442.86. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Other large investors have modified their holdings of the company. American Capital Management Inc. increased its stake in shares of Idexx Laboratories by 19.6% in the fourth quarter. American Capital Management Inc. now owns 647,856 shares of the company’s stock valued at $47,242,000 after buying an additional 106,310 shares in the last quarter. Principal Financial Group Inc. increased its stake in Idexx Laboratories by 1.8% in the fourth quarter. Principal Financial Group Inc. now owns 296,034 shares of the company’s stock worth $21,587,000 after buying an additional 5,318 shares during the period. Howland Capital Management LLC increased its stake in Idexx Laboratories by 2.3% in the fourth quarter. Howland Capital Management LLC now owns 300,331 shares of the company’s stock worth $21,900,000 after buying an additional 6,737 shares during the period. Morgan Stanley increased its stake in Idexx Laboratories by 41.3% in the fourth quarter. Morgan Stanley now owns 272,672 shares of the company’s stock worth $19,883,000 after buying an additional 79,704 shares during the period. Finally, Mutual of America Capital Management LLC increased its stake in Idexx Laboratories by 0.3% in the fourth quarter. Mutual of America Capital Management LLC now owns 61,367 shares of the company’s stock worth $4,475,000 after buying an additional 187 shares during the period.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.